Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06664879 · ClinicalTrials.gov registry record · Phase 1
ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial
A Phase 1 study of AML, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT06664879: Active Phase 1 study of AML, sponsored by M.D. Anderson Cancer Center.
NCT06664879 is a Phase 1 study of AML that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants, below the 133-participant average among 29 other AML trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06664879, a Phase 1 study of AML, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
To demonstrate the efficacy of targeted and tailored sequential therapy in patients with AML.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG MBG-453 + Azacitidine
Study Locations (1)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2024-12-30 |
| Est. Completion | 2028-07-31 |
| Phase | Phase 1 |
What the registry record for NCT06664879 still lists
NCT06664879 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 29 other AML trials with a reported enrollment target (98% lower).
The record links to 1 condition, with AML appearing as the primary indexed condition, and to 1 intervention - of which MBG-453 + Azacitidine is the first listed.
NCT06664879 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06664879 about?
NCT06664879 is a clinical study titled "ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial". To demonstrate the efficacy of targeted and tailored sequential therapy in patients with AML.
What is the current status of trial NCT06664879?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2024-12-30. Estimated completion is 2028-07-31.
What conditions does trial NCT06664879 study?
This clinical trial studies the following conditions: AML.
What interventions are being tested in trial NCT06664879?
The interventions under investigation include: MBG-453 + Azacitidine (DRUG).
Who is sponsoring clinical trial NCT06664879?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06664879 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AML
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06664879's enrollment target sits among peer trials
3 29th of 29 the lowest of 29 other AML trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other AML trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
CC-486 and Venetoclax for Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI